之江生物(688317.SH):磐信投資已累計減持3765.37萬股
格隆匯3月7日丨之江生物(688317.SH)公佈,公司於2022年3月7日收到股東磐信投資關於股份減持進展的吿知函,磐信投資於2022年2月22日至2022年3月4日期間通過集中競價的方式減持5,347,507股,佔公司總股本的2.75%,本次集中競價減持計劃數量過半;同時在2022年1月18日至2022年3月4日期間,其通過大宗交易的方式減持32,306,200股,合計減持3765.37萬股其持有的公司股份。
截至2022年3月4日,磐信投資持有公司的股份數量為1,800,555股,佔公司總股本的比例為0.92%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.